Education
About Us
Working with TipRanks
Follow Us
THNR - ETF AI Analysis
Top Page
Amplify Weight Loss Drug & Treatment ETF (THNR)
Rating:68Neutral
Price Target:―
Positive Factors
Leading Drug Makers at the Top
The fund’s largest positions include major pharmaceutical companies with generally strong recent performance, which can help support returns.
Focused Exposure to Weight-Loss Treatments
The ETF is heavily invested in health care and weight-loss drug makers, giving investors targeted exposure to a fast-growing treatment area.
Recent Performance Momentum
The fund has shown positive performance over the past few months, suggesting improving momentum in its underlying holdings.
Negative Factors
High Sector Concentration
With nearly all assets in health care, the ETF is heavily exposed to risks specific to drug pricing, regulation, and medical innovation.
Dependence on a Few Large Holdings
A small number of big pharmaceutical stocks make up a large share of the portfolio, so weakness in these names could significantly hurt returns.
Relatively High Expense Ratio
The fund’s management fee is on the higher side for an ETF, which can eat into long-term returns compared with lower-cost options.
THNR vs. SPDR S&P 500 ETF (SPY)
AUM4.24M
RegionDeveloped Markets
Expense Ratio0.59%
Beta0.72
IssuerAmplify
Inception DateMay 21, 2024
Dividend Yield1.65%
Asset ClassEquity
Index TrackedVettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,343
30 Day Avg. Volume3,467
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
29.81Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
THNR Summary
The Amplify Weight Loss Drug & Treatment ETF (THNR) tracks the VettaFi Weight Loss Drug & Treatment Index and focuses on health care companies working on obesity and weight loss treatments. It mainly holds big drugmakers like Novo Nordisk and Eli Lilly, along with other global pharmaceutical and biotech firms. Someone might invest in this ETF to bet on the long-term growth of weight loss drugs and to get diversified exposure to several leading companies instead of picking a single stock. A key risk is that it is heavily concentrated in health care and weight loss drugs, so it can be very volatile and may fall if the sector or these treatments lose momentum.
How much will it cost me?The Amplify Weight Loss Drug & Treatment ETF (THNR) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise required to select investments.
What would affect this ETF?The Amplify Weight Loss Drug & Treatment ETF (THNR) could benefit from growing global awareness of obesity-related health issues and increased demand for innovative weight loss treatments, especially as its top holdings include major pharmaceutical companies like Eli Lilly and Novo Nordisk, which are leaders in this space. However, the ETF may face challenges from regulatory hurdles, competition in drug development, or economic downturns that could reduce consumer spending on health care solutions. Additionally, its heavy reliance on the health care sector makes it vulnerable to sector-specific risks, such as changes in government policies or patent expirations.
THNR Top 10 Holdings
This ETF is a pure play on weight-loss and obesity treatments, and it leans heavily on a handful of big drugmakers to set the tone. Eli Lilly and Novo Nordisk, once the market darlings of this theme, are now losing steam and acting as a drag on returns. In contrast, names like Amgen, Merck, and AstraZeneca are steadily pulling their weight, while Japanese players Shionogi and Chugai are quietly rising stars. With all holdings in developed markets and almost entirely in health care, this is a highly concentrated, pharma-focused bet.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.33% | $523.35K | $943.21B | 21.66% | 72 Outperform | |
| Novo Nordisk | 9.85% | $418.21K | $171.65B | -50.43% | 73 Outperform | |
| Amgen | 7.88% | $334.37K | $203.57B | 20.84% | 77 Outperform | |
| Chugai Pharmaceutical Co | 7.35% | $311.83K | ¥15.56T | 37.92% | 74 Outperform | |
| Regeneron | 6.92% | $293.88K | $81.88B | 12.35% | 78 Outperform | |
| Shionogi & Co | 6.11% | $259.40K | ¥3.04T | 43.17% | 75 Outperform | |
| Merck & Company | 5.88% | $249.68K | $287.32B | 25.43% | 80 Outperform | |
| AstraZeneca | 5.37% | $227.70K | $300.81B | 24.33% | 80 Outperform | |
| Roche Holding AG | 5.30% | $224.94K | CHF263.94B | 29.32% | 73 Outperform | |
| Pfizer | 5.18% | $219.82K | $155.24B | 6.18% | 74 Outperform |
THNR Technical Analysis
Negative
―
Price Trends
25.91
Negative
25.06
Negative
23.88
Positive
Market Momentum
-0.29
Positive
40.73
Neutral
60.03
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For THNR, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 25.78, equal to the 50-day MA of 25.91, and equal to the 200-day MA of 23.88, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 40.73 is Neutral, neither overbought nor oversold. The STOCH value of 60.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for THNR.
THNR Peer Comparison
Comparison Results
Performance Comparison
THNR
Amplify Weight Loss Drug & Treatment ETF
25.03
3.18
14.55%
AGNG
Global X Aging Population ETF
―
―
―
JEDI
Defiance Drone and Modern Warfare ETF
―
―
―
WCBR
WisdomTree Cybersecurity Fund
―
―
―
FDIQ
Invesco Bloomberg Financial Data Providers ETF
―
―
―
WISE
Themes Generative Artificial Intelligence ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents